Lastacaft

Lastacaft is a brand name of alcaftadine ophthalmic, approved by the FDA in the following formulation(s):

LASTACAFT (alcaftadine - solution/drops; ophthalmic)

• 
  Manufacturer: ALLERGAN
  
  Approval date: July 28, 2010
  
  Strength(s): 0.25% ^[RLD]

Has a generic version of Lastacaft been approved?

No. There is currently no therapeutically equivalent version of Lastacaft available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lastacaft. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Imidazo[2,1-b]benzazepine derivatives, compositions and method of use
  Patent 5,468,743
  Issued: November 21, 1995
  Inventor(s): Janssens; Frans E. & Diels; Gaston S. M. & Leenaerts; Joseph E.
  Assignee(s): Janssen Pharmaceutica N.V.
  The present invention is concerned with novel imidazo[2, 1-b][3]benzazepines of formula ##STR1## the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein each of the dotted lines independently represents an optional bond; R.sup.1 represents hydrogen, halo, C.sub.1-4 alkyl or C.sub.1-4 alkyloxy; R.sup.2 represents hydrogen, halo, C.sub.1-4 alkyl or C.sub.1-4 alkyloxy; R.sup.3 represents hydrogen, C.sub.1-4 alkyl, ethenyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, hydroxyC.sub.1-4 alkyl, formyl or hydroxycarbonyl; R.sup.4 represents hydrogen, C.sub.1-4 alkyl, hydroxyC.sub.1-4 alkyl, phenyl or halo; R.sup.5 represents hydrogen, C.sub.1-4 alkyl or halo; L represents hydrogen; C.sub.1-6 alkyl; C.sub.1-6 alkyl substituted with one substituent selected from the group consisting of hydroxy, halo, C.sub.1-4 alkyloxy, hydroxycarbonyl, C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyloxycarbonyl-C.sub.1-4 alkyloxy, hydroxycarbonylC.sub.1-4 alkyloxy, C.sub.1-4 alkyloxycarbonylamino, C.sub.1-4 alkylaminocarbonyl, C.sub.1-4 alkylaminocarbonylamino, C.sub.1-4 alkylaminothiocarbonylamino, aryl, aryloxy and arylcarbonyl; C.sub.1-6 alkyl substituted with both hydroxy and aryloxy; C.sub.3-6 alkenyl; C.sub.3-6 alkenyl substituted with aryl; or, L represents a radical of formula --Alk--Y--Het.sup.1 (a-1),--Alk--NH--CO--Het.sup.2 (a-2)or --Alk--Het.sup.3 (a-3); provided that 6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine is ecxluded, which are useful antiallergic compounds. Compositions comprising said compounds, methods of using and processes for preparing the same.
  
  Patent expiration dates:
  
  
  • November 21, 2012
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 28, 2015 - NEW CHEMICAL ENTITY
  
  

See also...

• Lastacaft Consumer Information (Drugs.com)
• Lastacaft Drops Consumer Information (Wolters Kluwer)
• Lastacaft Consumer Information (Cerner Multum)
• Lastacaft Advanced Consumer Information (Micromedex)
• Lastacaft AHFS DI Monographs (ASHP)
• Alcaftadine Drops Consumer Information (Wolters Kluwer)
• Alcaftadine ophthalmic Consumer Information (Cerner Multum)
• Alcaftadine Ophthalmic Advanced Consumer Information (Micromedex)
• Alcaftadine AHFS DI Monographs (ASHP)